Welcome to our dedicated page for TriSalus Life Sciences SEC filings (Ticker: TLSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to decode how TriSalus funds its Pressure Enabled Drug Delivery (PEDD) platform or when nelitolimod might reach pivotal trials? Biotech filings can span hundreds of pages packed with medical jargon and accounting footnotes. Our SEC hub turns TriSalus Life Sciences SEC filings explained simply into a reality鈥攏o more hunting for pipeline costs or FDA correspondence across scattered documents.
Stock Titan鈥檚 AI reads every TriSalus Life Sciences quarterly earnings report 10-Q filing, annual report 10-K simplified, and 8-K material events explained the moment they hit EDGAR. It surfaces answers to real investor questions like 鈥渦nderstanding TriSalus Life Sciences SEC documents with AI鈥� or 鈥淲hat鈥檚 in the TriSalus Life Sciences proxy statement executive compensation?鈥� You鈥檒l also see real-time alerts for TriSalus Life Sciences Form 4 insider transactions real-time, letting you track TriSalus Life Sciences executive stock transactions Form 4 alongside AI-powered context鈥攚as that purchase timed before a Phase 2 data read-out?
Need practical insights fast? Our dashboard pulls out exactly where the 10-K details PEDD revenue, highlights cash-runway notes in the 10-Q, and flags 8-K disclosures on device approvals. Key features include:
- AI summaries that condense complex oncology language into plain English
- Instant updates on TriSalus Life Sciences insider trading Form 4 transactions
- Side-by-side TriSalus Life Sciences earnings report filing analysis for trend spotting
Whether you鈥檙e vetting immuno-oncology pipelines or comparing R&D burn rates, our platform delivers the full story behind every document鈥攕o you can act on data, not guesswork.
TriSalus Life Sciences reported accelerating product revenue and improved liquidity but continues to record operating losses and faces substantial doubt about its ability to continue as a going concern. Revenue for Q2 2025 rose to $11.213 million from $7.364 million a year earlier, producing gross profit of $9.411 million for the quarter and $17.083 million for the six months ended June 30, 2025, compared with $11.938 million a year earlier. Cash and cash equivalents increased to $26.8 million at June 30, 2025 from $8.5 million at year-end 2024, driven primarily by a $22.0 million private placement and draws under the OrbiMed Credit Agreement.
The company reported a six-month net loss available to common stockholders of $18.663 million and an accumulated deficit of $298.2 million. Total assets were $41.3 million versus total liabilities of $60.7 million, producing a stockholders' deficit of $19.4 million. Management disclosed substantial doubt about near-term liquidity and expects to require additional capital through collaborations, equity or debt to fund operations.
TriSalus Life Sciences, Inc. (TLSI) filed a Form 4 on 27-Jun-2025 for director Arjun J. Desai. On 12-Jun-2025 Desai received a grant of 15,000 non-qualified stock options at an exercise price of $5.50 per share. The options will fully vest on the earlier of (i) 12-Jun-2026 or (ii) the company鈥檚 next annual shareholder meeting, subject to continued service. They expire on 11-Jun-2035. After this grant, Desai beneficially owns 65,000 derivative securities; no common shares were acquired or sold, and ownership remains direct. The filing represents routine director compensation and does not disclose any open-market transactions.
FAQ
What is the current stock price of TriSalus Life Sciences (TLSI)?
What is the market cap of TriSalus Life Sciences (TLSI)?
